Case report: Small cell neuroendocrine carcinoma (2009)

Record number: 
Adverse Occurrence type: 
MPHO Type: 
Estimated frequency: 
Most recent risk assessment for neuroendocrine tumors (including high grade neuroendocrine carcinomas, low(er) grade neuroendocrine tumors, carcinoid tumors, pheochromocytomas and paragangliomas) (Council of Europe, 2022): Due to their potential for undetected metastasis, high-grade neuro-endocrine carcinomas are an unacceptable risk for organ donation. Insufficient information exists to guide practice for neuro-endocrine tumours, carcinoid tumours, phaeochromocytomas and paragangliomas. In the case of critically ill recipients, these tumours might be acceptable after a careful individual risk–benefit analysis. Neuro-endocrine tumours in the donor history: No data are available from the literature. Due to this and their potential for undetected metastasis, treated high-grade neuro-endocrine neoplasms in the donor history are classified as high risk for organ donation. In the case of a previous history (> 5 years) of neuro-¬endocrine tumours (carcinoid tumours, phaeochromocytomas and paragangliomas) without any kind of disease recurrence or progression, donors should be considered high risk in the absence of sufficient information to guide practice.
Time to detection: 
4 months
Alerting signals, symptoms, evidence of occurrence: 
Liver: 4 months after Tx, liver nodules on routine abdominal Ultrasound and CT scan, During surgery peritoneal spread found. Biochemical markers and biopsy performed and compatible with neuroendocrine tumour.
Demonstration of imputability or root cause: 
2 recipients affected, 1 unaffected (left kidney explanted due to primary non-function with no evidence of tumour infiltration or transmission). DNA fingerprint analyses.
Imputability grade: 
3 Definite/Certain/Proven
Suggest references: